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Gap junctions form the cell-to-cell pathways for propagation of the precisely orchestrated patterns of
current ﬂow that govern the regular rhythm of the healthy heart. As in most tissues and organs, multiple
connexin types are expressed in the heart: connexin43 (Cx43), Cx40 and Cx45 are found in distinctive
combinations and relative quantities in different, functionally-specialized subsets of cardiac
myocyte. Mutations in genes that encode connexins have only rarely been identiﬁed as being a cause
of human cardiac disease, but remodelling of connexin expression and gap junction organization are
well documented in acquired adult heart disease, notably ischaemic heart disease and heart failure.
Remodelling may take the form of alterations in (i) the distribution of gap junctions and (ii) the
amount and type of connexins expressed. Heterogeneous reduction in Cx43 expression and disordering
in gap junction distribution feature in human ventricular disease and correlate with electrophysiologi-
cally identiﬁed arrhythmic changes and contractile dysfunction in animal models. Disease-related
alterations in Cx45 and Cx40 expression have also been reported, and some of the functional impli-
cations of these are beginning to emerge. Apart from ventricular disease, various features of gap junc-
tion organization and connexin expression have been implicated in the initiation and persistence of the
most common form of atrial arrhythmia, atrial ﬁbrillation, though the disparate ﬁndings in this area
remain to be clariﬁed. Other major tasks ahead focus on the Purkinje/working ventricular myocyte
interface and its role in normal and abnormal impulse propagation, connexin-interacting proteins and
their regulatory functions, and on deﬁning the precise functional properties conferred by the distinctive
connexin co-expression patterns of different myocyte types in health and disease.
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1. Introduction
Gap junctions are clusters of transmembrane channels which,
by directly linking the cytoplasmic compartments of neigh-
bouring cells, form conduits for direct intercellular communi-
cation (review
1). In cells in general, gap-junctional
intercellular communication plays a key role in tissue homeo-
stasis and regulation of growth, development, and differen-
tiation. In the heart, gap junctions mediate electrical
coupling between cardiac myocytes, forming the cell-to-cell
pathways for orderly spread of the wave of electrical exci-
tation responsible for synchronous contraction (reviews
2,3).
The normal heart rhythm thus depends fundamentally on
the coupling of cardiac myocytes by gap junctions. Disturb-
ances of the normal cardiac rhythm (arrhythmias) are a
common, serious and often fatal complication of many
forms of heart disease. Abnormalities in the active membrane
properties responsible for the action potential play a central
part in the genesis of arrhythmia, but it is now recognized
that gap junctions and their component connexins also play
an important role. Here, we examine the role of gap junc-
tions in heart disease, focusing in particular on the nature
and functional signiﬁcance of the alterations to gap junction
organization and connexin expression referred to as ‘gap
junction remodelling’. To provide the background from
which disease-related alterations can be interpreted, we
start with a summary of the principal features of gap junc-
tions and connexin expression in the normal adult heart.
2. Gap junction organization and connexin
expression in the normal adult heart
Gap junctions in the heart vary enormously in size, from tens
of thousands to fewer than ten channels. Each gap junction
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channels), one contributed by each of the apposed plasma
membranes. The connexon spans the full depth of the mem-
brane and is constructed from six connexin molecules.
Twenty different connexin types have been identiﬁed in
mouse and 21 in man.
4 The speciﬁc connexin type or mix
of connexin types within the connexon permits differen-
tiation of the functional properties of the channel (review
5).
Three principal connexins are expressed in cardiac myo-
cytes, connexin43 (Cx43), Cx40, and Cx45. Although Cx43
predominates in the heart as a whole, it is typically
co-expressed in characteristic combinations and relative
quantities with Cx40 and/or Cx45 in a chamber-related
and myocyte-type-speciﬁc manner.
6,7 Although a few other
connexins have been reported in cardiac tissue, these are
minor components, species variants, or, where early
reports have not been conﬁrmed, are likely to be the
product of mistaken interpretation. Figure 1 gives an over-
view of the typical connexin expression patterns of the
normal adult mammalian heart.
The working (contractile) myocytes of the ventricle are
extensively interconnected by clusters of Cx43-containing
gap junctions (Figure 2). The gap junctions are organized,
together with two types of adhesion junction—fasciae
adherentes junctions and desmosomes—at the intercalated
discs (Figure 3). The intercalated disc has a characteristic
irregular, step-like structure, exquisitely specialized for
the task of integrating cell-to-cell electro-mechanical func-
tion. Fasciae adherentes junctions, which transmit mechan-
ical force from cell to cell, are situated in the vertical
‘steps’ of the disc, linking up the myoﬁbrils of adjacent
cells in series. Desmosomes, often likened to ‘press studs’
between cells, form attachment sites for the desmin cytos-
keleton, and are found predominantly in the intervening
horizontal portions of the disc. Most of the gap junctions
are also found in these horizontal segments, often with
larger junctional plaques at the disc periphery. Atrial myo-
cytes similarly have abundant gap junctions, but in contrast
to their ventricular counterparts, in most mammalian
species (including humans) these junctions are constructed
from both Cx43 and Cx40
8 and are organized in less well
demarcated intercalated discs (Figure 4). In both ventricular
and atrial human myocardium, Cx45 is detected in low quan-
tities, with higher levels in the atria than the ventricles.
7
The myocytes of the impulse generation and conduction
system are quite distinct from the contractile ventricular
and atrial cells, both morphologically and with respect to
their connexin expression proﬁles.
9–11 Myocytes of the
sinoatrial and atrioventricular (AV) nodes characteristically
have small, dispersed gap junctions composed of Cx45
and, in the case of the mouse, also Cx30.2, connexins that
form low conductance channels in vitro.
10–13 These features
suggest relatively poor coupling which, in the AV node may
contribute to slowing of impulse propagation, thus ensuring
sequential contraction of the cardiac chambers. Within the
AV node, complex, compartmentalized connexin expression
patterns are apparent; three-dimensional reconstruction of
the rabbit AV node, for example, reveals that while the
compact node and transitional cells predominantly express
Cx45, the His bundle, lower nodal cells and posterior nodal
extension co-express Cx45 with Cx43.
14 Downstream from
the His bundle, the conduction system myocytes of most
mammals, including man, prominently express Cx40.
15,16
Cx43 becomes abundant in the more distal portions of the
system,
6,11,15 while Cx45 is expressed continuously from
the AV node to the ends of the Purkinje ﬁbres.
11
Though these features of connexin expression are common
to most mammalian species, there are notable exceptions.
For example, Cx40 is not detectable in rat atrium or the
guinea pig conduction system.
6,17 Species variations in
co-expression patterns within the AV node are apparent
between large and small mammals, possibly reﬂecting
differences in the need for impulse delay according to
Figure 1 Summary of the typical connexin expression patterns of the mam-
malian heart.
Figure 2 Characteristic distribution pattern of Cx43 gap junctions in ventri-
cular myocardium. (A) Longitudinal section from rat left ventricle. The Cx43
gap junctions appear in rows, corresponding to edge-on viewed intercalated
discs. Inset shows a single intercalated disc viewed face-on from transversely
sectioned human myocardium. Note larger gap junctions at the periphery of
the disc. (B) The presence of multiple discs of different size is best appreci-
ated in views of isolated myocytes (in this example, from rat). The steps of
the disc are indicated by the white line. Note that some apparently isolated
gap junctions at the lateral surface (indicated by spot on the line) can be con-
sidered as components of extended intercalated discs.
N.J. Severs et al. 10Figure 3 Organization of junctions at the intercalated disc, as seen by thin-section electron microscopy. In low magniﬁcation view (A), the step-like features of
the discs are clearly seen (right end of cell and arrowheads). If we take, at higher magniﬁcation, an area from within the disc like that enclosed by the box, the
three junction types are visible (B). Fasciae adherentes occupy electron-dense vertical plicate zones of the disc; gap junctions and desmosomes mainly the
lateral-facing zones. In this example, the ends of the gap junction contact a fascia adherens (arrows), though in many instances non-junctional intercalated
disc plasma membrane separates the junctions from one another [(A) from Severs, N.J. et al J Ultrastruct Res 1982;81:222–239; reprinted with permission
from Elsevier; (B) from Severs, N.J. BioEssays 2000;22:188–199].
Figure 4 Variations in the pattern of organization of gap junctions in atrial myocardium, as seen by Cx43 labelling in dissociated groups of rat atrial myocytes.
While clusters of gap junctions in classic step-like and straight-end intercalated disc conﬁgurations are present [lines, left side of cells in (A) and (B)], the junc-
tions often appear spread laterally (asterisks). Gap junction distribution can thus range from largely end-to-end (C) to predominantly side-to-side (D).
Gap junction remodelling 11heart size.
18 That Cx31.9 is present in the human AV node
has been inferred from the presence of its orthologue,
Cx30.2, in the mouse AV node, but comprehensive investi-
gation shows no evidence for such a localization (unpub-
lished observations, in collaboration with K.Willecke and
M.Kreuzberg, University of Bonn). Such species differences
in connexin expression, and those of cardiac function,
need to be borne in mind when extrapolating functional
data from transgenic mice to the human.
3. Mutations in connexin-encoding genes
Although our primary focus here is on gap junction remodel-
ling and arrhythmia in acquired adult heart disease, we
should not overlook the possible consequences of defects
in gap-junctional communication as a potential cause of
developmental malformations of the heart. As in non-
excitable tissues, cardiac myocyte gap junctions have the
potential to act as pathways for the direct passage of signal-
ling molecules and ions from cell to cell, and that they may
do so during cardiac morphogenesis is suggested by the pre-
sence of developmental malformations in connexin knock-
out mice.
19–22
Reports that mutations of the Cx43 gene (GJA1) affecting
phosphorylation sites in the Cx43 carboxy tail are associated
with complex cardiac malformations and visceroatrial het-
erotaxia
23 or hypoplastic left heart syndrome
24 generated
major interest. Subsequent studies, however, failed to
conﬁrm this link
25,26 though as these did not examine
cardiac tissue, the possibility remains that somatic
mutations may explain some of the original ﬁndings.
23 A
range of mutations in the Cx43 gene are, however, clearly
associated with oculodentodigital dysplasia, a developmen-
tal abnormality affecting the limbs, teeth, face, and eyes,
and, in some instances, also the heart.
27–29
Chromosomal deletion that includes the Cx40 gene (GJA5)
has been reported in a minority of cases of congenital heart
disease involving anomalies of the aortic arch.
30 Heterozy-
gous somatic missense mutations and polymorphisms
within the gene’s regulatory region
31,32 have also been
linked to atrial ﬁbrillation (AF).
4. Disease-related remodelling of gap
junctions and connexin expression
That alterations in gap junction organization and connexin
expression contribute to abnormal impulse propagation
and arrhythmia in acquired adult heart disease has gained
progressively wider acceptance (reviews
2,3). In any discus-
sion of this topic, however, it is important to bear in mind
that arrhythmias are multi-factorial in origin, involving an
interplay between gap-junctional coupling, membrane
excitability, and cell and tissue architecture.
33 Gap-
junctional coupling will itself be determined by a number
of factors, including the amount and types of connexin
expressed, the size and distribution of gap-junctional
plaques, the proportion of each connexin assembled into
functional junctions, and the gating and speciﬁc connexin
make-up of individual gap-junctional channels.
4.1 Acute cardiac ischaemia
Acute focal cardiac ischaemia resulting from sudden occlu-
sion of a coronary artery triggers major alterations in
impulse formation and propagation. Action potential
upstroke velocity decreases, conduction transiently
increases and then slows, and changes in refractory period
ensue, resulting in localized conduction block and re-entry
arrhythmia. The changes are not uniform across the affected
region, and ectopic foci arise within the ventricle. Although
the effects of acute ischaemia on human cardiac gap junc-
tions are difﬁcult to investigate directly, studies on exper-
imental animals demonstrate rapid dephosphorylation of
Cx43, electrical uncoupling and alteration in the distribution
of gap junction immunolabel to the sides of the myocyte
(referred to as ‘lateralization’).
34,35 Immunolabelling using
antibodies directed to different phosphorylation sites on
the Cx43 molecule suggests that dephosphorylated Cx43 is
associated with the laterally distributed gap junction
label, while those gap junctions that remain in the classic,
polar intercalated disc orientation contain phosphorylated
Cx43.
35 While the altered distribution of gap junction
label, as viewed by immunoﬂuorescence microscopy in
these studies, is striking, it remains unclear what proportion
of the lateral signal is attributable to potentially functional
gap junctions connecting side-by-side myocytes, and what
proportion represents vesicles of gap-junctional membrane
that are internalized as a result of stress.
The adverse effects of ischaemia on gap junctions are
reduced with ischaemic preconditioning.
36–38 Roles for the
gap junction and Cx43 other than those related to
cell-to-cell electrical coupling and arrhythmia have been
put forward in interpreting ﬁndings on ischaemia, precondi-
tioning and ischaemia-reperfusion. Transient opening of
Cx43 hemichannels that lie free in the plasma membrane,
external to gap junctions, has been implicated in cell swel-
ling, ATP release, and loss of membrane potential during
ischaemia,
39,40 though the presence of pannexin rather
than connexin hemichannels has been suggested as an
alternative explanation for such phenomena.
41 Gap-
junctional mediated passage of ionic/molecular signals
appears responsible for the spread of the
ischaemia-reperfusion injury from myocyte to myocyte
that leads to rigour contracture and cell death,
42 an idea
supported by the observation that reduction of gap junction
coupling (using heptanol) prior to an ischaemic insult results
in signiﬁcantly reduced infarct size.
43 Cx43 trafﬁcked to
mitochondria (rather than that located in functional gap
junctions) has been invoked as central to the part played
by Cx43 in preconditioning, and a number of candidate
mechanisms for this has been proposed (review
44). The
beneﬁt of preconditioning on infarct size is apparently abol-
ished in heterozygous Cx43 knock-out mice which express
half the normal level of Cx43,
45 yet coronary occlusion in
these mice reportedly leads to smaller infarcts than in
their wild-type counterparts.
46 This discrepancy may be
related to the timing of infarct size measurement.
4.2 Altered gap junction distribution and reduced
connexin43 expression in diseased ventricle
‘Lateralization’ of Cx43 gap junction label is a prominent
feature of the border zone of surviving myocytes around
infarct scar tissue in the human ventricle,
47 a ﬁnding that
pre-dated the descriptions of this phenomenon in animal
models of acute infarction. Electron microscopy reveals
that both laterally disposed gap junctions connecting
N.J. Severs et al. 12adjacent cells, and internalized (non-functional) gap-
junctional membrane, contribute to this abnormal
pattern.
47 A similar change, found in some rat models of
ventricular hypertrophy, correlates with reduced longitudi-
nal conduction velocity, a potentially pro-arrhythmic
change.
48 At 4 days post-infarction in a dog model, lateral
gap junction label in the extended infarct border zone has
been correlated spatially with electrophysiologically ident-
iﬁed ﬁgure-of-eight re-entrant circuits.
49 Gap-junctional
changes distant from the infarct scar tissue, in particular
reduction in the size and the number of gap junctions per
unit length of intercalated disc, and fewer side-to-side con-
nections between myocytes, have been described as longer
term remodelling events in dog myocardium.
50
Smaller areas of gap junction disarray than those found at
the infarct border zone have been reported in end-stage
humanheartfailureduetoidiopathicdilatedcardiomyopathy
and myocarditis,
51 and inthe ventricles of patients with com-
pensated hypertrophy due to valvular aortic stenosis.
52 In
decompensated hypertrophy from the same cause, patches
are seen in which the otherwise normally arrayed gap junc-
tions are fewer or absent.
52 These ﬁndings emphasize that
evenintheabsenceofinfarcts,Cx43gapjunctiondistribution
becomes heterogeneous in disease. Cx43 gap junction
arrangement is particularly disordered in hypertrophic cardi-
omyopathy, the most common cause of sudden cardiac death
due to arrhythmia in young adults; here the abnormal gap
junction distribution is dictated by the haphazard myocyte
organization characteristic of this condition.
53
A rather different form of gap junction remodelling is
associated with ‘hibernating myocardium’ in patients with
ischaemic heart disease.
54 The term ‘hibernating myocar-
dium’ refers to regions of ventricular myocardium that do
not contract properly but which recover after normal
blood ﬂow is restored following coronary artery by-pass
surgery. In hibernating myocardium, the large Cx43 gap
junctions typically found at the periphery of the interca-
lated disc are smaller in size, and the overall amount of
immunodetectable Cx43 per intercalated disc is reduced,
compared with normally perfused myocardial regions of
the same heart.
54 These ﬁndings were the ﬁrst indication
that Cx43 gap junction remodelling contributes to impaired
ventricular contraction, in addition to arrhythmia, in human
ischaemic heart disease.
54
Apart from alterations in Cx43 gap junction organization,
marked reduction in ventricular Cx43 transcript and protein
levels typify the hearts of transplant patients with end-stage
congestive heart failure. This Cx43 reduction occurs irre-
spective of whether heart failure is due to ischaemic heart
disease, idiopathic dilated cardiomyopathy, or aortic steno-
sis.
51,52,55–57 The reduction in Cx43 is spatially hetero-
geneous and develops progressively during the course of
disease, as indicated by the pattern of change observed in
pressure-overloaded hearts with aortic stenosis
52 and its
presence in non-failing ventricles of patients with ischaemic
heart disease.
58
4.3 Does reduced connexin43 contribute
to ventricular arrhythmia?
AcriticalquestioniswhetherthereducedCx43inthediseased
human ventricle contributes to the arrhythmic substrate. It is
commonly assumed that such reductions in Cx43 inexorably
result in slowed conduction, thereby rendering the ventricle
moresusceptibletore-entryarrhythmia.Onthisbasis,thera-
peutic intervention to improve coupling is sometimes pro-
posed. However, theoretical and experimental cell models
show that action potential propagation can fail in well
coupled cells if these form a large mass (‘sink’) receiving a
limited amount of depolarizing current from a smaller
‘source’ (i.e. a ‘source/sink mismatch’); under these con-
ditions, reducing couplingin the‘sink’ can actually overcome
a conduction block.
33,59 Thus, reduction of Cx43, if of a mag-
nitude sufﬁcient to decrease coupling, could form part of a
protective response that increases the safety of conduction
in the diseased ventricle.
The mammalian heart, however, has a considerable
surfeit of gap junctions, and computer modelling predicts
that even substantial reductions in gap junction content
make relatively little difference to propagation velocity.
60,61
Apparently in keeping with these theoretical predictions,
the magnitude of the Cx43 reduction associated with
sudden cardiac death due to arrhythmia in the cardiac
restricted Cx43 knock-out mouse is in the order of 90%,
62
much greater than the average reduction of 50% observed
in the failing human ventricle.
55 However, this average dis-
guises considerable spatial heterogeneity in the extent of
the reduction, some regions of some diseased hearts reach-
ing a reduction of .90% of control values.
55 That heterogen-
eity in Cx43 expression is critical both to abnormal impulse
propagation and contractile dysfunction is elegantly demon-
strated experimentally in a chimaeric mouse model gener-
ated to give patches of myocardium lacking Cx43.
63
Heterogeneity of gap junction distribution combined with
reduced Cx43 levels appears to act co-operatively to
create an arrhythmogenic substrate at less severe levels of
overall gap junction reduction than predicted in theoretical
models. In selectively bred cardiac-restricted knock-out
mice, a 59% reduction in Cx43 does not alter propagation
velocity or susceptibility to arrhythmia, but when the Cx43
reduction reaches 18% of control levels and appears hetero-
geneous, propagation velocity is slowed by 50%, and 80% of
the animals are inducible into lethal ventricular arrhyth-
mias.
64 Co-operative effects of reduced Cx43 and other
factors, such as those related to acute ischaemia, may
also alter the threshold at which the arrhythmic substrate
is reached; a straightforward halving of the Cx43 level in
transgenic mice (i.e. Cx43
þ/Cx43
2) is sufﬁcient to increase
the incidence, frequency and duration of ventricular tachy-
cardias when the heart is subjected to ischaemia.
65
Taken together, these ﬁndings in mouse models lend con-
siderable support to the view that the nature and extent of
the Cx43 reduction in the failing human ventricle is, in prac-
tice, of sufﬁcient magnitude to increase susceptibility to
arrhythmia. It could be argued that such extrapolation
from mouse to man is limited because the mouse heart
cannot accommodate large re-entrant circuits; however, a
heterogeneous 50% reduction in Cx43, similar to that of
human heart failure, has been demonstrated to result in
slowed transmural conduction and dispersion of action
potential duration of a magnitude that exceeds the require-
ments for conduction block and re-entry in a dog model of
heart failure.
66 The results from experimental animal
models thus vindicate the conclusions originally suggested
from those on human cardiac disease.
54,55
Gap junction remodelling 134.4 Connexin45, connexin40, and the Purkinje/
working ventricular myocyte interface
Our discussion so far has, however, focused solely on Cx43 to
the exclusion of the other two connexins, Cx45 and Cx40.
One study has reported elevated expression of Cx45 in the
failing human ventricle, alongside the reduction in Cx43,
thus signiﬁcantly altering the Cx43:Cx45 ratio.
57 As Cx43
and Cx45 are reported to be assembled as mixtures in the
same connexon and channel,
67 this could potentially have
substantial effects on channel properties.
57 Experimental
increase of the Cx45:Cx43 ratio by over-expression of Cx45
in transgenic mice has recently been demonstrated to
increase susceptibility to ventricular tachycardia and
reduce gap-junctional intercellular communication.
68
Increased expression of Cx40 has also been found in the
failing human ventricle, but this increase is regionally
restricted and conﬁned to end-stage ischaemic heart
disease.
55 The site of Cx40 up-regulation is the endocardial
surface, at and adjacent to Purkinje ﬁbres, highlighting the
Purkinje/working ventricular myocyte interface or junction
as a potential site of altered electrical coupling that might
trigger arrhymogenesis. In cardiac-restricted Cx43 knock-
out mice selected for longer term survival, reduction of
coupling resulting from declining ventricular Cx43 leads to
propagation of the impulse across numerous Purkinje/
working ventricular myocyte junctions that normally
remain dormant, thereby creating abnormal activation
patterns and wave-front collisions in the ventricular myocar-
dium.
69 Essentially, what seems to be happening parallels
some of the classic experiments of Rohr
59 on patterned
cultures, in which reduced coupling in a sink (equivalent
to the ventricular myocardium) abolishes the conduction
block that otherwise occurs at the boundary with a narrow
source (equivalent to the Purkinje ﬁbre).
However, the Purkinje/working ventricular myocyte inter-
face in vivo is a more complex structure than a patterned
cell culture, involving the connection of Purkinje myocytes
that co-express Cx40, Cx45 and Cx43 to ventricular myocytes
expressing predominantly Cx43. The connection between the
two cell types is not direct, but mediated via distinctive ﬂat-
tened transitional cells running at an angle below the Pur-
kinje myocytes.
70 Examination of connexin expression
patterns in the mouse reveals that Cx40 and Cx45 are
co-expressed both in Purkinje myocytes and in the underlying
transitional cells, and that the Cx45 expression continues
down into the most superﬁcial layer of ventricular myocytes
(Figure 5). This suggests that Cx45 plays an important role
in connecting up the Cx40/Cx43 Purkinje myocyte compart-
ment to the Cx43-expressing working ventricle via the transi-
tional cells. Further work is required to establish the precise
cellular organization and nature of the connections at this
critical interface. Their cellular structure appears to differ
in the pig
70 from that illustrated in Figure 5 and so there
may well be differences between mouse and man.
Figure 5 The Purkinje/working ventricular myocyte interface. (A) Cellular architecture. Purkinje myocytes link to underlying ﬂattened transitional cells, which
in turn link to the working ventricular myocardium. (B) immunoconfocal view of Purkinje myocyte/working ventricular myocyte interface from mouse myocar-
dium showing transversely sectioned Purkinje myocytes (P) above a longitudinally sectioned transitional cell (T). The working ventricular myocyardium (WM) lies
below. Connexin immunolabelling shows that whereas Cx40 (C) is abundant in the Purkinje myocytes and transitional cells, Cx45 (D) is seen in both these cell
types and in the most superﬁcial working ventricular myocytes [asterisk, (B)].
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The wide recognition that gap junction remodelling is a
key contributor to ventricular arrhythmia has stimulated
corresponding studies on atrial arrhythmia and, in particu-
lar, AF, a particularly common arrhythmia in which wavelets
of electrical activity propagate in multiple directions.
However, the picture to emerge is not clear-cut, with a
range of disparate and seemingly contradictory ﬁndings.
For example, while studies using dog models report
increased Cx43 expression together with gap junction later-
alization,
71 other studies on a goat model of AF report no
changes in the overall level of Cx43 but development of het-
erogeneity of Cx40 distribution.
72 Studies in the human
confuse the picture still further, with reports linking AF var-
iously to increased Cx40, decreased Cx40, increased Cx43,
decreased Cx43, or no change in the level of either con-
nexin, and some reporting lateralization of gap junction dis-
tribution, whereas others claim increased heterogeneity.
73
How do we make sense of these apparently contradictory
ﬁndings? It is important to emphasize that the published
studies on animal models use different species at different
ages, with different experimental protocols for induction
of AF, and those on the human involve different clinical
sub-sets of patients with different associated pathological
factors. A key distinction has to be drawn between chronic
AF, in which remodelling of gap junctions and connexin
expression brought about as part of AF-related remodelling
might contribute to perpetuation of the condition,
71,74,75
and initiation of AF, in which pre-existing features of gap
junctions or connexin expression may act as a predisposing
factor that triggers off the arrhythmia in the ﬁrst
place.
76,77 In each category, we must bear in mind that AF
is multi-factorial in origin; hence the underlying mechanisms
and relative importance of gap junctions as contributors
may vary from one patient to the next. Moreover, in
chronic AF there will be temporal changes during the
course of disease, with a role for gap junctions likely assum-
ing greater or lesser importance at different stages, and
associated pathological changes such as atrial dilatation
(frequently found in patients with AF who undergo cardiac
surgery) may independently inﬂuence any changes in gap
junctions observed.
Another contributor to the confusion stems from
deﬁciencies of technical approach and interpretative com-
plications. Apart from the still too common problem of
lack of antibody speciﬁcity,
8,74,78,79 differences in epitope
detection between different antibodies to the same con-
nexin type have a major impact on localization patterns.
80
Claims of ‘lateralization’ and ‘heterogeneity’ of gap junc-
tion or connexin distribution as AF-related factors pose par-
ticularly tricky problems of interpretation. Normal atrial
myocardium shows considerable variation in gap junction
arrangement (Figure 4). While some atrial myocytes show
gap junctions organized in classic intercalated disc patterns
at the cell ends, others show ‘spread’ of the discs along the
lateral aspects of the cell (Figure 4A–C). This ‘lateral
spread’ is in part a product of the smaller diameter of
atrial myocytes compared with their ventricular counter-
parts, and in some instances can be so pronounced in
normal atrial myocardium that the predominant pattern is
of laterally distributed rather than polar gap junctions
(Figure 4D). ‘Lateralization’ should not be confused with
‘heterogeneity’, a term that is used to describe patches in
the tissue in which gap junctions or connexin label are
absent. The heterogeneity of Cx40 distribution reported as
an AF-induced change in the goat model
81,82 resembles
that naturally seen in the human atrium.
77,83 These con-
siderations complicate development of reliable quantitative
methods for assessment of differences in the distribution of
connexin label between normal and AF samples.
The challenge ahead is to develop a more reﬁned and rig-
orous approach to tease out precisely how gap junctions and
connexins might contribute to AF in different, deﬁned set-
tings. To this end, a series of useful recommendations has
recently been suggested by Duffy and Wit.
84
5. Co-expression of multiple connexins—
counter-intuitive properties
In retrospect, it appears that a major factor contributing to
the relative ease with which a link between gap junction
remodelling and arrhythmia in the ventricle has been estab-
lished is the presence of a single predominant connexin,
Cx43. Increasing evidence suggests that co-expression of
Cx40 in the presence of Cx43—as occurs in the atrium and
at the Purkinje/working ventricular myocyte interface—has
unexpected functional effects. Using in vitro expression
systems, it has consistently been found that Cx40, when
expressed alone, makes high conductance gap junction
channels, and it has been widely assumed that co-expression
of Cx40 with Cx43 in vivo would elevate rather than depress
cell-to-cell coupling.
85 However, in cultured neonatal atrial
myocytes from heterozygous Cx43 and Cx40 knock-out mice
(Cx43
þ/Cx43
2 and Cx40
þ/Cx40
2), reduction of Cx40 to half
the normal level results in increased propagation velocity,
and when Cx40 is ablated altogether (Cx40
2/Cx40
2), propa-
gation velocity is higher still.
86 Thus, progressively lowering
the Cx40 content against a background of Cx43 expression
unexpectedly leads to increased rather than decreased con-
duction. This helps make sense of previously perplexing ﬁnd-
ings, such as the positive correlation between propagation
velocity and decreased proportion of Cx40 to total connexin
reported in the human atrium.
87 How these effects are
mediated requires knowledge of the speciﬁc connexin
make-up of the junctions and their channels at the molecu-
lar level, and how this translates into speciﬁc electrophysio-
logical properties. Cell models, in which different multiple
connexins are expressed under the control of inducible pro-
moters and which are amenable to functional analysis, offer
one approach to advance this area.
3,88
6. Cellular mechanisms of gap junction
remodelling
Our understanding of the cellular mechanisms of gap junc-
tion remodelling remains fragmentary. As with all proteins,
connexin expression may be regulated at the transcriptional
and post-transcriptional levels. The interaction of transcrip-
tion factors with their target elements to control transcript
expression has advanced as our knowledge of the structure
of the genes encoding Cx43, Cx40 and Cx45 has pro-
gressed.
89 With regard to post-transcriptional regulation, a
recent study has identiﬁed a role for microRNA-1 in silencing
GJA1 (the Cx43-encoding gene) and KCNJ2 (K
þ channel
Gap junction remodelling 15subunit Kir2.1) in ischaemic heart disease.
90 MicroRNAs are
endogenous non-coding RNAs that interact with target
mRNAs to prevent translation; increased expression of
microRNA-1 is elevated in the diseased human ventricle,
and antisense blocking of this elevation prevents arrhythmia
in a corresponding animal model.
90
Apart from connexin synthesis, regulatory mechanisms
may come into play at the levels of assembly into connex-
ons, channels and gap-junctional plaques, and during degra-
dation. Extracellular signalling pathways leading to altered
connexin expression in disease may be triggered in part by
mechanical forces, and involve cAMP, angiotensin II, and
growth factors such as VEGF, activated via protein kinases
such as focal adhesion kinase and c-Jun N-terminal kinase
(JNK).
91,92 JNK activation in a transgenic mouse model
leads to down-regulation of Cx43, slowing of ventricular
conduction, contractile dysfunction and congestive heart
failure.
93
A major focus of current research concerns connexin
partner proteins, a series of proteins with regulatory proper-
ties that interact with the carboxy-terminal domain of Cx43
(review
94). This domain houses a series of functionally
important sites, notably those involved in channel gating
and phosphorylation (a process implicated in diverse roles
including trafﬁcking of connexins and junction assembly
and degradation). Apart from c-Src and adhesion junction
proteins, other connexin binding partners include tubulin,
caveolins, and zonula occludens-1 (ZO-1). Carboxy-terminal
binding sites for tubulin and associated motor transport pro-
teins mediate trafﬁcking of connexins to the correct desti-
nation at the cell surface, while ZO-1 is intimately
involved in regulation of gap junction size. In exogenous
expression systems, blocking or abolition of the binding of
ZO-1 to Cx43 leads to formation of exceptionally large,
extensive gap junctions, an effect that is reversed when
the capacity to interact is restored.
95 In human ventricular
myocytes, ZO-1 is localized to the intercalated disc, and a
pool of this ZO-1 interacts with Cx43 gap junctions.
96 In
the failing ventricle, although an association between
reduced ZO-1 and Cx43 levels has been reported,
97,98 we
ﬁnd that ZO-1 is, in fact, consistently up-regulated, and
that the proportion of Cx43 that interacts with ZO-1 is
increased (Figure 6).
96 ZO-1 appears to act by limiting the
recruitment of connexons to the gap junction periphery,
95
and in this way may contribute to reduced gap junction
size and overall gap junction content in the diseased
human heart.
96
The effects of ZO-1, however, are not mediated in iso-
lation, but in all likelihood involve co-operative actions
with other connexin interacting protein partners. Molecules
classically associated with adhesion junctions, notably N-
cadherin, b-catenin, g-catenin (plakoglobin), plakophilin-2
(PKP2) and desmoplakin, are among the partner proteins
that interact, either directly or via other proteins, with
Cx43. It has long been known that adhesion junction pro-
teins play a key role in the formation and stability of gap
junctions,
99–102 but it has only recently become apparent
that mutations in or suppression of these proteins can lead
to reductions in Cx43 expression and gap junction quantity
of sufﬁcient magnitude that impulse propagation is
impaired.
103–109 The notion of molecular ‘cross-talk’
between the components of the different junction types is
thus now very much in vogue.
110,111
Although the precise pathways are unclear, this molecular
‘cross-talk’ appears to be mediated both at the level of the
surface-located gap junction and within the cell. Apart from
its role in bonding fasciae adherentes junctions, for
example, N-cadherin is implicated in trafﬁcking and assem-
bly of Cx43 into functional gap junctions (review
108).
b-catenin, in addition to linking N-cadherin to actin of the
contractile apparatus, operates as an effector protein in
the Wnt signalling pathway; transcriptional activation via a
b-catenin/Tcf nuclear complex, for example, induces Cx43
expression in cultured cardiomyocytes.
112 In non-myocyte
cells, silencing b-catenin disrupts gap junction formation,
113
and over-expression of b-catenin leads to down-regulation
of ZO-1.
114 ZO-1 may, in fact, physically mediate the link
between the cadherin/catenin complex and Cx43
(review
108). PKP2, as well as being a structural component
of desmosomes, modulates the signalling activity of
b-catenin,
115 and loss of PKP2 leads to re-distribution of
Cx43 from the membrane to the cytosol.
105 In a transgenic
mouse model in which a truncated form of Cx43, lacking
the carboxy-terminal domain, is expressed, there is not
only an increased size of the gap junction plaques and a
reduction in their overall number, but also an altered
pattern of their spatial organization at the intercalated
disc.
116 The ability of protein partners to interact with the
carboxy-terminal domain thus appears to be crucial not
only in regulation of the size of gap junctions, but also
their correct positioning. The major task ahead is to
unravel the complex interactions between these molecules
and the signalling pathways involved, and how they link to
the various features of disease-related gap junction remo-
delling in the heart.
As the concept of ‘cross-talk’ between connexins and
adhesion junction molecules has raced ahead, basic concep-
tual problems have been left behind.
111 For example, classic
electron microscopy demonstrating the three types of cell
junction of the intercalated disc as spatially discrete struc-
tures implies corresponding spatially discrete sites for con-
nexins and adhesion molecules. Although associations and
interactions are commonly inferred from immunoﬂuores-
cence co-localization of adhesion junction proteins, ZO-1
and Cx43, this technique does not have the resolution to
tell us whether apparent overlap of ﬂuorescence signals
actually represents a sufﬁciently close association at the
molecular level to enable interaction or merely reﬂects a
Figure 6 (A) Cx43 is down-regulated and ZO-1 up-regulated in end-stage
heart failure, giving a signiﬁcant negative correlation (P ¼ 0.0029; r
2 ¼
0.51). (B) This is associated with an increased interaction of Cx43 with
ZO-1 in both non-junctional and gap-junctional fractions as determined by
co-immunoprecipitation (The non-junctional fraction is Triton X-100-soluble
and represents Cx43 not assembled into gap junctions). DCM, dilated cardio-
myopathy; ICM, ischaemic cardiomyopathy. *P ¼ 0.05 vs. controls. From
Bruce et al.
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N.J. Severs et al. 16more distant juxtaposition. We do not yet know where the
adhesion junction proteins postulated to interact with
Cx43 are actually located at the gap junction.
111 Are they
conﬁned to the periphery of the gap junction at sites at
which it is linked edge-to-edge with a neighbouring adhesion
junction, or are they spread along the gap junction’s entire
cytoplasmic face to exert more general regulatory effects?
What is the hierarchy of which protein interacts with
which in order to bind to Cx43? And what protein partners
correspondingly affect Cx40 and Cx45 via carboxy-terminal
domain interactions? These are but few of the questions
that remain to be resolved.
7. Concluding comments
It is now ﬁrmly established that remodelling of gap junction
and connexin expression does consistently feature in the dis-
eased human ventricle, and comparative studies on trans-
genic animal models and other experimental systems
provide substantial evidence that these alterations contrib-
ute to the arrhythmic substrate in the patient. Gap junctions
and connexins are thus increasingly debated as potential
therapeutic targets. However, the realization that reduced
coupling can increase the safety of conduction, and that
increasing the Cx40:Cx43 ratio may reduce rather than
increase conduction velocity, serve as important reminders
that, even if some of the proposed therapeutic interventions
were practicable, the functional consequences to the
patient may be the opposite of those intended. Key areas
of knowledge need to be consolidated to permit a more rea-
listic assessment of the possibilities. These include determi-
nation of: (i) the precise functional properties dictated by
the distinctive connexin co-expression patterns of different
myocyte types in health and disease; (ii) the regulatory
mechanisms underlying gap junction and connexin remodel-
ling; (iii) the nature and role of the Purkinje/ventricular
myocyte interface; (iv) the part played by gap junctions
and connexins in AF; and (v) the nature and action of
messenger molecules or ions involved in direct molecular
signalling. A thorough understanding of gap-junctional
intercellular communication in the normal and diseased
human heart must also underpin strategies that aim to inte-
grate transplanted cells with host myocardium as a potential
treatment for heart failure.
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